Latest content
-
ReadLearn the pros and cons of these 3 methods to serotype your AAV gene therapy vectors
-
37:25WatchPut your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
-
ReadNanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail
NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
-
2:20WatchIntroducing Monolith X - the only way to get binding affinities in solution using very minimal sample
-
Read
The only way to get binding affinities in solution using very minimal sample
-
Read
Select the best biologics candidates with high-quality, multi-parameter stability characterization
-
Read5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
-
Read
Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust
-
14:07WatchSerotyping: why, when, and how to assess your AAV therapeutic to get it approved
When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part
- Contact Specialist
-
Read
Rely on Dianthus to overcome roadblocks in your PROTAC characterizations
-
ReadNanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer
MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...
-
Read8 Gene Therapy conferences you should attend in 2022
With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...
-
Read9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
-
ReadGet more information about your protein expression conditions in less time with Andromeda
Get more information about your protein expression conditions in less time with Andromeda
-
ReadWays light scattering technologies help you if you’re in gene therapy
-
Read
Four technologies to profile your AAVs
-
ReadNanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine optimal protein labeling strategy
MUNICH/DRESDEN, April 6, 2022—NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help...
-
Read10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
-
ReadNanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
-
Read
Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus
-
Loading more...
